Severity of Liver Disease Affects HCV Kinetics in Patients Treated with Intravenous Silibinin Monotherapy | Zendy

Laëtitia Canini | Zendy; Swati DebRoy | Zendy; Zoe Mariñó | Zendy; Jessica M. Conway | Zendy; Gonzalo Crespo | Zendy; Miquel Navasa | Zendy; Massimo D’Amato | Zendy; Péter Ferenci | Zendy; Scott J. Cotler | Zendy; Xavier Forns | Zendy; Alan S. Perelson | Zendy; Harel Dahari | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Severity of Liver Disease Affects HCV Kinetics in Patients Treated with Intravenous Silibinin Monotherapy

Author(s) -

Laëtitia Canini,

Swati DebRoy,

Zoe Mariñó,

Jessica M. Conway,

Gonzalo Crespo,

Miquel Navasa,

Massimo D’Amato,

Péter Ferenci,

Scott J. Cotler,

Xavier Forns,

Alan S. Perelson,

Harel Dahari

Publication year - 2014

Publication title -

antiviral therapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.747

H-Index - 87

eISSN - 2040-2058

pISSN - 1359-6535

DOI - 10.3851/imp2806

Subject(s) - medicine , gastroenterology , cirrhosis , silibinin , liver disease , liver transplantation , hepatitis c , chronic liver disease , viral hepatitis , viral load , transplantation , immunology , pharmacology , virus

HCV kinetic analysis and modelling during antiviral therapy have not been performed in decompensated cirrhotic patients awaiting liver transplantation. Here, viral and host parameters were compared in three groups of patients treated with daily intravenous silibinin (SIL) monotherapy for 7 days according to the severity of their liver disease.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research